Literature DB >> 25703879

Persistence of iatrogenic atrial septal defect after interventional mitral valve repair with the MitraClip system: a note of caution.

Robert Schueler1, Can Öztürk1, Jan Arne Wedekind2, Nikos Werner1, Florian Stöckigt1, Fritz Mellert3, Georg Nickenig1, Christoph Hammerstingl4.   

Abstract

OBJECTIVES: The purpose of this study was to investigate the persistence rates of iatrogenic atrial septal defect (iASD) after interventional edge-to-edge repair with serial transesophageal echocardiography examinations and close clinical follow-up (FU).
BACKGROUND: Transcatheter mitral valve repair (TMVR) with the MitraClip system (Abbott Vascular, Abbott Park, Illinois) is a therapeutic alternative to surgery in selected high-risk patients. Clip placement requires interatrial transseptal puncture and meticulous manipulation of the steerable sheath. The persistence of iASD after MitraClip procedures and its clinical relevance is unknown.
METHODS: A total of 66 patients (76.7% male, mean age 77.1 ± 7.9 years) with symptomatic mitral regurgitation (MR) at prohibitive surgical risk (EuroSCORE II 10.1 ± 6.1%) underwent MitraClip procedures and completed 6 months of FU.
RESULTS: Transesophageal echocardiography after FU showed persistent iASD in 50% of cases. Patients with iASD did not significantly differ from patients without ASD concerning baseline characteristics, New York Heart Association functional class, severity of MR, and acute procedural success rates (p > 0.05). When comparing procedural details and hemodynamic measures between groups, MitraClip procedures took longer in patients without iASD (82.4 ± 39.7 min vs. 68.9 ± 45.5 min; p = 0.05), and echocardiography after FU showed less decrease of systolic pulmonary artery pressures in the iASD group (-1.6 ± 14.1 mm Hg vs. 9.3 ± 17.4 mm Hg; p = 0.02). Clinically, patients with iASD presented more often with New York Heart Association functional classes >II after FU (57% vs. 30%; p = 0.04), showed higher levels of N-terminal pro-brain natriuretic peptide (6,667.3 ± 7,363.9 ng/dl vs. 4,835.9 ± 6,681.7 ng/dl; p = 0.05), and had less improvement in 6-min walking distances (20.8 ± 107.4 m vs. 114.6 ± 116.4 m; p = 0.001). Patients with iASD showed higher death rates during 6 months (16.6% vs. 3.3%; p = 0.05). Cox regression analysis found that only persistence of iASD (p = 0.04) was associated with 6-month survival.
CONCLUSIONS: The persistence rate of 50% iASD after MitraClip procedures is considerably high. Persistent interatrial shunting was associated with worse clinical outcomes and increased mortality. Further studies are warranted to investigate if persistent interatrial shunting is the mediator or marker of advanced disease in these patients.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MitraClip; heart failure; iatrogenic ASD; prognosis

Mesh:

Year:  2015        PMID: 25703879     DOI: 10.1016/j.jcin.2014.10.024

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  20 in total

1.  Antegrade transcatheter mitral valve-in-valve implantation with combined atrial septal defect closure.

Authors:  Felipe C Fuchs; Christoph Hammerstingl; Jan-Malte Sinning; Fritz Mellert; Nikos Werner; Eberhard Grube; Georg Nickenig
Journal:  Clin Res Cardiol       Date:  2015-11-09       Impact factor: 5.460

Review 2.  Echocardiographic evaluation and guidance for MitraClip procedure.

Authors:  William E Katz; Anson J Conrad Smith; Frederick W Crock; João L Cavalcante
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

3.  Initial Slovenian experience with MitraClip therapy : Careful selection of patients is crucial for optimal outcome.

Authors:  Jana Ambrožič; Marta Cvijič; Mojca Bervar; Špela Mušič; Matjaž Bunc
Journal:  Wien Klin Wochenschr       Date:  2017-12-04       Impact factor: 1.704

4.  High rate of persistent iatrogenic atrial septal defect after single transseptal puncture for cryoballoon pulmonary vein isolation.

Authors:  Markus Linhart; Jessica T Werner; Florian Stöckigt; Annika T Kohlmann; Pia C Lodde; Lutz P T Linneborn; Thomas Beiert; Christoph Hammerstingl; Roger Borràs; Georg Nickenig; René P Andrié; Jan W Schrickel
Journal:  J Interv Card Electrophysiol       Date:  2018-03-24       Impact factor: 1.900

Review 5.  ASD Closure in Structural Heart Disease.

Authors:  Dominik M Wiktor; John D Carroll
Journal:  Curr Cardiol Rep       Date:  2018-04-17       Impact factor: 2.931

6.  Persistent iatrogenic atrial septal defects after pulmonary vein isolation: long-term follow-up with contrast transesophageal echocardiography.

Authors:  Allan Davies; Prasad Gunaruwan; Nicholas Collins; Malcolm Barlow; Nick Jackson; James Leitch
Journal:  J Interv Card Electrophysiol       Date:  2016-09-28       Impact factor: 1.900

Review 7.  Pulmonary Hypertension in Patients Eligible for Transcatheter Mitral Valve Repair: Prognostic Impact and Clinical Implications.

Authors:  Evin Yucel; Rasha Al-Bawardy; Philippe B Bertrand
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-10

Review 8.  Left ventricular decompression in veno-arterial extracorporeal membrane oxygenation.

Authors:  Ashleigh Xie; Paul Forrest; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2019-01

Review 9.  Haemodynamic and functional consequences of the iatrogenic atrial septal defect following Mitraclip therapy.

Authors:  E A Hart; K Zwart; A J Teske; M Voskuil; P R Stella; S A J Chamuleau; A O Kraaijeveld
Journal:  Neth Heart J       Date:  2017-02       Impact factor: 2.380

10.  Ischemic Stroke or Systemic Embolism After Transseptal Ablation of Arrhythmias in Patients With Cardiac Implantable Electronic Devices.

Authors:  Malini Madhavan; Xiaoxi Yao; Lindsey R Sangaralingham; Samuel J Asirvatham; Paul A Friedman; Christopher J McLeod; Alan M Sugrue; Christopher V DeSimone; Peter A Noseworthy
Journal:  J Am Heart Assoc       Date:  2016-04-13       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.